Obstetrics & Gynecology Doctors in Seminole, TX Accepting Medicare

3 Obstetrics & Gynecology doctors found. Showing 1 - 3

Wendell W Parkey, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 207 Nw 8th St, Seminole, TX 79360 Phone: 432-758-1155    Fax: 432-758-4740

Dr. Armand L Wiltz, M.D. Obstetrics & Gynecology - Gynecology Medicare: Not Enrolled in Medicare Practice Location: 207 Nw 8th Street, Seminole, TX 79360 Phone: 432-758-1155    Fax: 432-758-4740

Gilbert George Sayegh, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1004 Hobbs Hwy, Suite 4, Seminole, TX 79360 Phone: 281-496-2496    Fax: 432-758-6509

News Archive

Access Pharmaceuticals to present two oncology posters at CPR Conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.

Decline in reducing youth smoking and increase in smokeless tobacco use

The 2009 Monitoring the Future Survey released today by the National Institute of Drug Abuse shows that the nation continues to make gradual progress in reducing youth smoking, but declines have slowed significantly compared to the dramatic gains early in the decade. In especially troubling news, the survey also finds that smokeless tobacco use has increased among 10th and 12th graders in recent years, a period during which tobacco companies have introduced a slew of new smokeless tobacco products and significantly increased marketing for smokeless tobacco.

Researchers identify new genetic regions associated with heart attacks

In the largest genetic study of Coronary Artery Disease (CAD) to date, researchers from the CARDIoGRAMplusC4D Consortium report the identification of 15 genetic regions newly associated with the disease, bringing to 46 the number of regions associated with CAD risk.

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that consolidation treatment with fractionated yttrium-90 (Y-90) labeled epratuzumab, after induction therapy with rituximab and CHOP (R-CHOP) chemotherapy, improved remission status of adult patients with diffuse large B-cell lymphoma (DLBCL), a form of aggressive lymphoma.

EADV survey: Almost half of the European general population have a dermatological condition

Results of a new EADV survey released today show that almost half (47.9%) of the European general population more than 18 years old declared at least one dermatological condition in the past 12 months.

Read more Medical News

› Verified 9 days ago